BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 30266754)

  • 1. RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer.
    Zarei M; Lal S; Vaziri-Gohar A; O'Hayer K; Gunda V; Singh PK; Brody JR; Winter JM
    Mol Cancer Res; 2019 Feb; 17(2):508-520. PubMed ID: 30266754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells.
    Zarei M; Lal S; Parker SJ; Nevler A; Vaziri-Gohar A; Dukleska K; Mambelli-Lisboa NC; Moffat C; Blanco FF; Chand SN; Jimbo M; Cozzitorto JA; Jiang W; Yeo CJ; Londin ER; Seifert EL; Metallo CM; Brody JR; Winter JM
    Cancer Res; 2017 Aug; 77(16):4460-4471. PubMed ID: 28652247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant IDH1 is required for IDH1 mutated tumor cell growth.
    Jin G; Pirozzi CJ; Chen LH; Lopez GY; Duncan CG; Feng J; Spasojevic I; Bigner DD; He Y; Yan H
    Oncotarget; 2012 Aug; 3(8):774-82. PubMed ID: 22885298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors.
    Chitneni SK; Reitman ZJ; Spicehandler R; Gooden DM; Yan H; Zalutsky MR
    Bioorg Med Chem Lett; 2018 Feb; 28(4):694-699. PubMed ID: 29366652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.
    Molenaar RJ; Botman D; Smits MA; Hira VV; van Lith SA; Stap J; Henneman P; Khurshed M; Lenting K; Mul AN; Dimitrakopoulou D; van Drunen CM; Hoebe RA; Radivoyevitch T; Wilmink JW; Maciejewski JP; Vandertop WP; Leenders WP; Bleeker FE; van Noorden CJ
    Cancer Res; 2015 Nov; 75(22):4790-802. PubMed ID: 26363012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer.
    Burkhart RA; Pineda DM; Chand SN; Romeo C; Londin ER; Karoly ED; Cozzitorto JA; Rigoutsos I; Yeo CJ; Brody JR; Winter JM
    RNA Biol; 2013 Aug; 10(8):1312-23. PubMed ID: 23807417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants.
    Avellaneda Matteo D; Wells GA; Luna LA; Grunseth AJ; Zagnitko O; Scott DA; Hoang A; Luthra A; Swairjo MA; Schiffer JM; Sohl CD
    Biochem J; 2018 Oct; 475(20):3221-3238. PubMed ID: 30249606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
    Mohrenz IV; Antonietti P; Pusch S; Capper D; Balss J; Voigt S; Weissert S; Mukrowsky A; Frank J; Senft C; Seifert V; von Deimling A; Kögel D
    Apoptosis; 2013 Nov; 18(11):1416-1425. PubMed ID: 23801081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
    Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
    J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis.
    Tiburcio PDB; Xiao B; Berg S; Asper S; Lyne S; Zhang Y; Zhu X; Yan H; Huang LE
    Acta Neuropathol; 2018 Feb; 135(2):285-298. PubMed ID: 29288440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low pH Facilitates Heterodimerization of Mutant Isocitrate Dehydrogenase IDH1-R132H and Promotes Production of 2-Hydroxyglutarate.
    Sesanto R; Kuehn JF; Barber DL; White KA
    Biochemistry; 2021 Jun; 60(25):1983-1994. PubMed ID: 34143606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate.
    Dexter JP; Ward PS; Dasgupta T; Hosios AM; Gunawardena J; Vander Heiden MG
    J Biol Chem; 2018 Dec; 293(52):20051-20061. PubMed ID: 30381394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
    Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W
    J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
    Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
    PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Insights for Inhibiting Mutant Heterodimer IDH1
    Juritz EI; Bascur JP; Almonacid DE; González-Nilo FD
    Mol Diagn Ther; 2018 Jun; 22(3):369-380. PubMed ID: 29651790
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Peeters TH; Lenting K; Breukels V; van Lith SAM; van den Heuvel CNAM; Molenaar R; van Rooij A; Wevers R; Span PN; Heerschap A; Leenders WPJ
    Cancer Metab; 2019; 7():4. PubMed ID: 31139406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TOF-SIMS analysis of an isocitrate dehydrogenase 1 mutation-associated oncometabolite in cancer cells.
    Park J; Na HK; Shon HK; Son HY; Huh YM; Lee SW; Lee TG
    Biointerphases; 2018 Jan; 13(3):03B404. PubMed ID: 29382206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells.
    Hujber Z; Petővári G; Szoboszlai N; Dankó T; Nagy N; Kriston C; Krencz I; Paku S; Ozohanics O; Drahos L; Jeney A; Sebestyén A
    J Exp Clin Cancer Res; 2017 Jun; 36(1):74. PubMed ID: 28578659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterozygous IDH1
    Wei S; Wang J; Oyinlade O; Ma D; Wang S; Kratz L; Lal B; Xu Q; Liu S; Shah SR; Zhang H; Li Y; Quiñones-Hinojosa A; Zhu H; Huang ZY; Cheng L; Qian J; Xia S
    Oncogene; 2018 Sep; 37(38):5160-5174. PubMed ID: 29849122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
    Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH
    Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.